Study details
Enrolling now
Viral Infection in Asthma (VIA) Trial
University of Virginia
NCT IDNCT04380038ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
60
Study length
about 4.7 years
Ages
18–40
Locations
1 site in VA
About this study
Researchers are testing if a treatment called dupilumab helps prevent asthma symptoms after being exposed to the common cold virus. Dupilumab is an injectable drug that blocks inflammation in the lungs. The trial will involve adults and track asthma symptoms using lung function tests, questionnaires, and other methods.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Dupilumab Injectable Product
PhasePhase 4
DrugDupilumab Injectable Product
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
injection
Endpoints
Secondary: Change in symptoms post-rhinovirus inoculation
Body systems
Respiratory